LONDON--(BUSINESS WIRE)--GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an ...

GlaxoSmithKline’s Nucala has suffered against a more convenient AstraZeneca rival, but the company finally has an answer. Thursday, the FDA greenlighted two new delivery options for Nucala: an ...

Nucala (mepolizumab) is a brand-name subcutaneous injection that comes in different forms. Depending on which form you’re prescribed, you or your doctor will administer the injection. Nucala injection ...

In its heated severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace in the fact that its drug was more convenient for patients, with a self-administered injection option.

Previously, the treatment had only been available as a lyophilized powder for reconstitution that required administration by a healthcare professional. The Food and Drug Administration has approved ...

The US Food and Drug Administration (FDA) has approved two new methods for administering mepolizumab (Nucala, GlaxoSmithKline), an autoinjector and a prefilled safety syringe, which patients or ...

Treatment with Nucala, an interleukin-5 antagonist monoclonal antibody, significantly reduced exacerbations leading to hospitalizations and emergency department visits. The Food and Drug ...

As with other drugs, Nucala injections can cause side effects, such as fatigue and back pain. Most side effects of Nucala are mild, temporary, and generally go away on their own. Nucala’s side effects ...

Nucala helps patients with severe eosinophilic asthma cut exacerbations and is now available in a prefilled pen for home injection. This bestseller drives the price of GSK shares (ISIN GB0009252882).